This study is exploring a medicine called resmetirom for people with a liver condition called well-compensated NASH cirrhosis. NASH stands for Non-Alcoholic Steatohepatitis, which is a liver disease that happens without alcohol use and can lead to cirrhosis (liver scarring). The study is double-blind, meaning neither the researchers nor the participants know who is getting the real medicine or a placebo (a fake pill). Participants take an 80 mg pill of resmetirom or placebo once each morning.

Researchers will watch for certain health events, such as liver or heart problems, to see how well the medicine works. This study will last about three years, with some checks every now and then. Participants are chosen randomly, like flipping a coin, to be in one of the two groups.

• The study includes a screening period of up to 60 days and a treatment period of about 3 years.
• You must have well-compensated NASH cirrhosis and meet specific health criteria to join.
• Participants must not have other chronic liver diseases or a history of liver problems.